Literature DB >> 427002

Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia.

G L Jennings, A Bobik, E T Fagan, P I Korner.   

Abstract

1 Pharmacokinetics of pindolol were studied in normal subjects given 5, 10 and 20 mg orally and 3 mg i.v. Plasma half time was 2.9 +/- 0.3 (s.e. mean) h for both routes; peak drug levels occurred 1--2 h after ingestion and bioavailability was 53%. Plasma protein binding was 38% and was independent of plasma concentration; the drug was not concentrated in the red cell. 2 Work-heart rate regression lines were calculated from resting heart rate and three grades of 'steady-state' exercise standardized for the maximum work capacity (Wmax) of each subject. The equation was characterized by slope and HR50 (calculated heart rate at 0.5 Wmax). 3 After giving 5 mg i.v. pindolol to produce maximum cardiac beta-adrenoceptor blockade there were differences in inhibition of resting heart rate, slope, HR50 and maximum heart rate suggesting differences in sympathetic components. However, estimates of the degree of inhibition were closely similar for each variable when determined before and after atropinization indicating that the accuracy of estimation was independent of the level of vagal activity. 4 After oral pindolol peak inhibition of resting heart rate, slope and HR50 coincided with peak plasma concentration. Peak reduction of resting heart rate was greatest at the lowest dose, but inhibition of slope and HR50 were similar at all doses. 5 The different heart rate parameters recovered at different rates. After 24 h slope had returned to control, and the residual inhibition of HR50 reflected residual beta-adrenoceptor blockade of resting heart rate, as demonstrated by a shift in isoprenaline-heart rate relationship. 6 Inhibition of HR50 and other exercise parameters were 20% less in the concentration range 5--20 ng/ml than peak inhibition obtained in the range 21--160 ng/ml. The higher potency of pindolol compared with propranolol can be accounted for by the difference in protein binding.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 427002      PMCID: PMC1429499          DOI: 10.1111/j.1365-2125.1979.tb00929.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Pharmacokinetics of oxprenolol in normal subjects.

Authors:  W D Mason; N Winer
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

Review 2.  The assessment of beta-adrenoceptor blocking drugs in man.

Authors:  D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

3.  A comparison of intravenous pindolol and propranolol in normal man.

Authors:  D C Hicks; A G Arbab; P Turner; M Hills
Journal:  J Clin Pharmacol New Drugs       Date:  1972 May-Jun

4.  The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat.

Authors:  G H Evans; A S Nies; D G Shand
Journal:  J Pharmacol Exp Ther       Date:  1973-07       Impact factor: 4.030

5.  Pharmacokinetics of pindolol in man.

Authors:  R Gugler; W Herold; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.

Authors:  G Johnsson; C G Regàrdh
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

7.  Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man.

Authors:  D J Coltart; D G Shand
Journal:  Br Med J       Date:  1970-09-26

8.  A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine.

Authors:  W L Pacha
Journal:  Experientia       Date:  1969-08-15

9.  beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

Review 10.  Uses of beta-adrenoceptor blocking drugs.

Authors:  B N Prichard; D G McDevitt; R G Shanks
Journal:  J R Coll Physicians Lond       Date:  1976-10
View more
  10 in total

1.  Increases in plasma beta-endorphin concentrations during exercise do not contribute to increases in heart rate following autonomic blockade in man.

Authors:  A Shen; J Chin; M Fullerton; G Jennings; A Dart
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

2.  Continuous Intestinal Absorption Model Based on the Convection-Diffusion Equation.

Authors:  Swati Nagar; Richard C Korzekwa; Ken Korzekwa
Journal:  Mol Pharm       Date:  2017-07-31       Impact factor: 4.939

3.  Influence of intrinsic sympathomimetic activity of beta-adrenoceptor blockers on the heart rate and blood pressure responses to graded exercise.

Authors:  G Jennings; A Bobik; P Korner
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

4.  Estimation of the absolute oral bioavailability of pindolol by two analytical methods.

Authors:  M Guerret; G Cheymol; J P Aubry; A Cheymol; D Lavene; J R Kiechel
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Effects of beta blockade on work--delta ST segment curves during exercise, and relation to subsequent results of coronary artery bypass surgery.

Authors:  G Jennings; A Pitt; G Stirling; P Korner
Journal:  Br Heart J       Date:  1980-04

6.  Cardiac dose-response relationships of oral and intravenous pindolol.

Authors:  S G Carruthers
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

7.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

8.  Concentration-effect and time-effect relationships of carteolol.

Authors:  T Ishizaki; A Ohnishi; T Sasaki; K Chiba; T Suganuma; K Kushida
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Bioavailability of dihydroergotamine in man.

Authors:  P J Little; G L Jennings; H Skews; A Bobik
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

10.  Beta-blocking effect and pharmacokinetics of pindolol in young and elderly hypertensive patients.

Authors:  I Gretzer; G Alván; H Dunér; M Garle; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.